NCT06573528

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Randomized, Double-Blind, Placebo-Controlled Single and Multiple Dose Escalations of CS060380 in Healthy and Elevated LDL-C Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 104 (actual)
• Sponsor: Cascade Pharmaceuticals, Inc · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects.

Detailed description

A Phase I study Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effects of Randomised, Double-Blind, Placebo-Controlled Single and Multiple Dose Escalations of CS060380 in Healthy and Elevated LDL-C Subjects.

Conditions

• MASH

Interventions

Type	Name	Description
DRUG	CS060380	Tablets administered orally

Timeline

• Start date: 2024-09-03
• Primary completion: 2025-05-09
• Completion: 2025-05-21
• First posted: 2024-08-27
• Last updated: 2025-08-13

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study